Literature DB >> 30975469

Reducing NETO2 expression prevents human nasopharyngeal carcinoma (NPC) progression by suppressing metastasis and inducing apoptosis.

Ai-Rong He1, Qiang Zhu2, Shang Gao3.   

Abstract

Nasopharyngeal carcinoma (NPC), the most common cancer in head and neck regions, is a serious health problem worldwide. Neuropilin and tolloid-like 2 (NETO2), a member of the subfamily of CUB domain and LDLa-containing proteins, has been suggested to be involved in tumor progression. Nevertheless, little is known about the function and molecular mechanism of NETO2 in NPC progression. In the study, NETO2 was found to be significantly up-regulated in clinical tissues and NPC cell lines. NETO2 expression was positively correlated with tumor size. NETO2 knockdown inhibited cell proliferation, migration and invasion in NPC cell lines. Significantly, NETO2 knockdown promoted the radiotherapy in vitro, as evidenced by the further reduced cell proliferation and metastasis in NPC cells using 3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide (MTT), colony formation and transwell analysis. In addition, NETO2 inhibition markedly induced apoptosis in NPC cells through activating Caspase-3 signaling. Also, the knockdown of NETO2 obviously promoted the efficacy of radiotherapy in apoptosis induction, along with higher expression of cleaved Caspase-3. NETO2 knockdown-triggered apoptosis in NPC cells were considerably diminished by Caspase-3 inactivation, demonstrating the essential role of Caspase-3 in NETO2-regulated NPC development. Moreover, in vivo experiments suggested that NETO2 knockdown promoted radiation-induced tumor growth suppression in the absence of significant side effects. Collectively, reducing NETO2 expression might elevate the efficiency of radiotherapy in NPC patients.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Caspase-3; Metastasis; NETO2; Nasopharyngeal carcinoma (NPC); Radiotherapy

Mesh:

Substances:

Year:  2019        PMID: 30975469     DOI: 10.1016/j.bbrc.2019.03.061

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  NETO2 Is Deregulated in Breast, Prostate, and Colorectal Cancer and Participates in Cellular Signaling.

Authors:  Maria S Fedorova; Anastasiya V Snezhkina; Anastasiya V Lipatova; Vladislav S Pavlov; Anastasiya A Kobelyatskaya; Zulfiya G Guvatova; Elena A Pudova; Maria V Savvateeva; Irina A Ishina; Tatiana B Demidova; Nadezhda N Volchenko; Dmitry Y Trofimov; Gennady T Sukhikh; George S Krasnov; Anna V Kudryavtseva
Journal:  Front Genet       Date:  2020-12-10       Impact factor: 4.599

2.  Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR-206 to upregulate NETO2 and FOXP1 expression.

Authors:  Chunyu Zhang; Yan Luo; Jingjing Cao; Xiaoyu Wang; Zhiwei Miao; Guoqing Shao
Journal:  Cancer Med       Date:  2020-10-02       Impact factor: 4.452

3.  NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway.

Authors:  Jia-Cheng Xu; Tian-Yin Chen; Le-Tai Liao; Tao Chen; Quan-Lin Li; Jia-Xin Xu; Jian-Wei Hu; Ping-Hong Zhou; Yi-Qun Zhang
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.